INCYClinical Trials•businesswire•
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
Sentiment:Positive (80)
Summary
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 15, 2025 by businesswire